Century Therapeutics, Inc.
Century Therapeutics, Inc.（IPSC）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · IPSC · 截至 2025年9月30日
股东结构概览
54
机构持有人数
▼ 13 vs Q2
$10.12M
机构持仓总市值
▼ $2.53M vs Q2
86.57M
总流通股
freeFloat 56.19%
20.30M
13F 申报持股数
▼ 2.32M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
IPSC 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC biological products, (no diagnostic substances) | 3.54M | 4.10% | 4.10% | $1.76B | Nov 14, 2025 | ▼ 1.87M |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 2.59M | 3.00% | 3.00% | $1.29B | Nov 13, 2025 | ▲ 564.4K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.10M | 2.44% | 2.44% | $1.05B | Nov 7, 2025 | ▼ 6.2K |
DAFNA CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 1.70M | 1.98% | 1.98% | $848.71M | Nov 14, 2025 | — held |
CASDIN CAPITAL, LLC biological products, (no diagnostic substances) | 1.23M | 1.42% | 1.42% | $611.64M | Nov 14, 2025 | — held |
SYNCONA PORTFOLIO LTD biological products, (no diagnostic substances) | 1.21M | 1.41% | 1.41% | $604.10M | Nov 6, 2025 | — held |
TWO SIGMA INVESTMENTS, LP biological products, (no diagnostic substances) | 911.4K | 1.06% | 1.06% | $453.90M | Nov 14, 2025 | ▲ 338.9K |
TANG CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 900.0K | 1.04% | 1.04% | $448.20M | Nov 14, 2025 | — held |
TWO SIGMA ADVISERS, LP biological products, (no diagnostic substances) | 857.6K | 99.45% | 99.45% | $427.08M | Nov 14, 2025 | ▲ 490.5K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 743.8K | 86.25% | 86.25% | $370.40M | Nov 14, 2025 | ▼ 68.4K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
10
增持
+2.42M 股2
新建仓
首次建仓25
减持
−4.32M 股0
清仓
完全退出净股数变化（前50家）
1.90M
+2.42M / −4.32M
净新增持仓人
-13
新建 2 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
IPSC 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
0
买入笔数
2
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Pfeiffenberger Brent President and CEO | May 15, 2026 | Tax Withhold | 31,172 | $2.34 | $72.9K | 3.68M | Form 4 ↗ |
Carr Douglas SVP Finance & Operations | May 4, 2026 | Sale | 264 | $2.34 | $618.024 | 507.0K | Form 4 ↗ |
Murphy Martin Patrick director | Dec 9, 2025 | Award | 88,000 | $0.59 | $52.1K | 88.0K | Form 4 ↗ |
Cowan Chad Chief Scientific Officer | Apr 1, 2026 | Tax Withhold | 1,365 | $2.19 | $3.0K | 1.18M | Form 4 ↗ |
Carr Douglas SVP Finance & Operations | Mar 12, 2026 | Sale | 7,043 | $2.55 | $18.0K | 507.3K | Form 4 ↗ |
Russotti Gregory See Remarks | Mar 12, 2026 | Sale | 10,076 | $2.55 | $25.7K | 515.4K | Form 4 ↗ |
Pfeiffenberger Brent President and CEO | Mar 11, 2026 | Tax Withhold | 55,397 | $2.73 | $151.2K | 3.71M | Form 4 ↗ |
Cowan Chad Chief Scientific Officer | Mar 11, 2026 | Tax Withhold | 1,431 | $2.73 | $3.9K | 1.18M | Form 4 ↗ |
Russotti Gregory See Remarks | Mar 9, 2026 | Sale | 479 | $2.54 | $1.2K | 525.5K | Form 4 ↗ |
Pfeiffenberger Brent President and CEO | Mar 6, 2026 | Tax Withhold | 463 | $2.56 | $1.2K | 3.77M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Century Therapeutics, Inc.（IPSC）主要由机构投资者持有，机构持股比例约为 23.4%。公司内部人员持股约 43.81%，散户及公众持股约占剩余的 32.74%。
Century Therapeutics, Inc. 最大机构股东为 BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC，截至 September 30, 2025 持有约 3.54 million 股，占总流通股的 4.10%。
目前共有 54 家机构持有 IPSC 股票，合计持仓市值约 $10,115,451，数据来源为最新 SEC 13F 申报。
常见问题
IPSC ownershipCentury Therapeutics, Inc.（IPSC）主要由机构投资者持有，机构持股约 23.4%。最大股东为 BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC，持股比例 4.10%。内部人员持股约 43.81%。数据来源 SEC Form 13F，截至 September 30, 2025。